Patent intelligence · US
US 8143218
Treatment of skin, and wound repair, with thymosin beta 4
Treatment of skin, and wound repair, with thymosin beta 4
Patent details — US 8143218
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 27, 2012
- Expiration
- Mar 22, 2032
- Applicant
- REGENERX BIOPHARMACEUTICALS, INC.
- Claims
- 21
- CPC classes
- A61K, A61K38/08, A61K38/1841, A61K38/2292
Quick answer
US 8143218 (Treatment of skin, and wound repair, with thymosin beta 4) is held by REGENERX BIOPHARMACEUTICALS, INC.. Status: granted. Granted Mar 27, 2012. Expires Mar 22, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- REGENERX BIOPHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K38/08, A61K38/1841, A61K38/2292, A61K45/06, A61K9/0048
More from REGENERX BIOPHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 8143218?
US 8143218 (Treatment of skin, and wound repair, with thymosin beta 4) is held by REGENERX BIOPHARMACEUTICALS, INC.. Status: granted. Granted Mar 27, 2012. Expires Mar 22, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8143218?
REGENERX BIOPHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 8143218 expire?
Our index shows an expiration date of Mar 22, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.